AT SDEF HAWAII DERMATOLOGY SEMINAR<\/p>\n
WAILEA, Hawaii <\/span>\u2013 The Food and Drug Administration approval of oxymetazoline 1% cream for the background erythema of rosacea is big news for dermatologists and patients, according to Linda Stein Gold, MD, director of dermatology research, Henry Ford Health System, Detroit. <\/span> <\/p>\n In studies, patients showed a two grade improvement in baseline erythema, and erythema reduction that lasted for 9-12 hours in many patients, said Dr. Stein Gold<\/a> in a video interview<\/a>, who was involved in the clinical trials. <\/p>\n \u201cWe have safety data that lasts up to an entire year, with no new safety signals,\u201d and the incidence of exacerbation of erythema was rare, she added in a video interview at<\/span> the meeting provided by Global Academy for Medical Education\/Skin Disease Education Foundation. Oxymetazoline<\/a> 1% cream, which will be marketed as Rhofade by Allergan, was approved in January 2017 for the \u201ctopical treatment of persistent facial erythema associated with rosacea in adults.\u201d <\/p>\n Dr. Stein Gold disclosed relationships with several companies, including Galderma, Leo, Novan, Valeant, Dermira, Novartis, Celgene, Allergan, Foamix, Anacor, Medimetriks, Sol-Gel, and Promius.<\/p>\n <\/span>SDEF and this news organization are owned by the same parent organization.<\/p>\n